It’s a rallying cry Alderman Joe Kelly Levasseur said he’s heard over the past week from resident across the city and state, ...

GLP-1s aren't FDA-approved to treat rheumatoid arthritis, but many people notice improvement in their inflammation with the ...

GLP-1 meds are trending after Serena Williams’ 31-pound weight loss. A doctor breaks down the side effects, safety concerns & ...

A study has found that adults with obesity taking GLP-1 receptor agonists may face significantly lower risk of developing certain cancers. The cohort study was led by researchers from the Indiana ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

As cancer progression has been linked with high glucose, adiposity, insulin resistance, and systemic inflammation, investigators studied several glucose-lowering drugs in relationship to cancer ...

"Losing weight is a choice. But it should never be made because of society’s aesthetic obsession with thinness." ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...

By now, you’ve probably heard about the weight-loss benefits of GLP-1 drugs like Ozempic (semaglutide ... The key policy question is how to push prices down even further. Denmark has been able to ...

Last year, GLP-1s dominated many employer conversations as demand surged and pressure mounted from employees clamoring for ...

GoodRx (NASDAQ:GDRX) jumped 18% after revealing a partnership with Novo Nordisk (NYSE:NVO) to offer Ozempic and Wegovy to eligible self-paying patients at a monthly price of $499. This agreement ...

As the Dec. 31 end to federal subsidies for federal health care nears, pressure is mounting on insurers, providers, and the ...